PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15464018-4 2004 In addition, the detection of the diverse receptor populations for ATP, noradrenaline and NPY in blood vessels, either in the smooth muscle, endothelial cells or nerve endings, further contribute to the notion that sympathetic vascular reflexes encompass the orchestrated action of the noradrenaline and ATP, and their modulation by NPY. Adenosine Triphosphate 304-307 neuropeptide Y Homo sapiens 90-93 19149635-1 2009 ATP is an important neurotransmitter being released with noradrenaline (NA) and neuropeptide Y (NPY) from perivascular sympathetic nerves; it acts at postjunctional P2X receptors to evoke vascular smooth muscle contraction, often synergising with the effects of NA acting at alpha-adrenoceptors. Adenosine Triphosphate 0-3 neuropeptide Y Homo sapiens 80-94 19149635-1 2009 ATP is an important neurotransmitter being released with noradrenaline (NA) and neuropeptide Y (NPY) from perivascular sympathetic nerves; it acts at postjunctional P2X receptors to evoke vascular smooth muscle contraction, often synergising with the effects of NA acting at alpha-adrenoceptors. Adenosine Triphosphate 0-3 neuropeptide Y Homo sapiens 96-99 18639636-5 2008 Moreover, NPY co-stimulation increases the potency of ATP for both ERK1/2 and TH phosphorylation, while having no effect on these parameters alone. Adenosine Triphosphate 54-57 neuropeptide Y Homo sapiens 10-13 16382997-4 2006 NPY plays a dual role as a modulator of sympathetic co-transmission; it facilitates vascular smooth muscle reactivity and modulates the presynaptic release of ATP and NA. Adenosine Triphosphate 159-162 neuropeptide Y Homo sapiens 0-3 15377822-7 2004 Moreover, NPY potentiated both the vasomotor action of ATP or NA alone and the vasoconstriction elicited by the simultaneous application of both cotransmitters. Adenosine Triphosphate 55-58 neuropeptide Y Homo sapiens 10-13 10205006-10 1999 A 5 min incubation of the biopsies with 10-100 nM NPY synergized, in a concentration-dependent fashion, both the ATP and the ATP analogue-induced contractions. Adenosine Triphosphate 113-116 neuropeptide Y Homo sapiens 50-53 11124136-0 2001 Substance P and NPY differentially potentiate ATP and adrenergic stimulated vasopressin and oxytocin release. Adenosine Triphosphate 46-49 neuropeptide Y Homo sapiens 16-19 11129543-10 2000 Exogenous application of NE and ATP contract saphenous vein rings; the simultaneous application of NE plus ATP causes a synergic response, effect which is further potentiated by the joint co-application of 10 nM NPY. Adenosine Triphosphate 32-35 neuropeptide Y Homo sapiens 212-215 11129543-10 2000 Exogenous application of NE and ATP contract saphenous vein rings; the simultaneous application of NE plus ATP causes a synergic response, effect which is further potentiated by the joint co-application of 10 nM NPY. Adenosine Triphosphate 107-110 neuropeptide Y Homo sapiens 212-215 10205006-10 1999 A 5 min incubation of the biopsies with 10-100 nM NPY synergized, in a concentration-dependent fashion, both the ATP and the ATP analogue-induced contractions. Adenosine Triphosphate 125-128 neuropeptide Y Homo sapiens 50-53 9020878-0 1997 Neuropeptide Y modulates ATP-induced increases in internal calcium via the adenylate cyclase/protein kinase A system in a human neuroblastoma cell line. Adenosine Triphosphate 25-28 neuropeptide Y Homo sapiens 0-14 10463216-0 1999 ATP release and degradation in the kidney: modulatory role of neuropeptide Y (NPY). Adenosine Triphosphate 0-3 neuropeptide Y Homo sapiens 62-76 10463216-0 1999 ATP release and degradation in the kidney: modulatory role of neuropeptide Y (NPY). Adenosine Triphosphate 0-3 neuropeptide Y Homo sapiens 78-81 9458879-4 1998 [Leu31,Pro34]NPY potentiated NE-induced and ATP-induced vasoconstriction, indicating the presence and biological action of Y1 receptors in this vascular bed. Adenosine Triphosphate 44-47 neuropeptide Y Homo sapiens 13-16 9458879-5 1998 The potentiation effect of [Leu31,Pro34]NPY of the increase in perfusion pressure by NE, ATP, or SNS was prevented by BIBP-3226. Adenosine Triphosphate 89-92 neuropeptide Y Homo sapiens 40-43 9458879-6 1998 In addition, SNS-induced vasoconstriction at both high and low frequencies was significantly attenuated by BIBP-3226 at a concentration that completely blocked the [Leu31,Pro34]NPY-induced potentiation of the NE- or ATP-induced vasoconstrictor effect. Adenosine Triphosphate 216-219 neuropeptide Y Homo sapiens 177-180 9020878-1 1997 The modulatory effects of neuropeptide Y (NPY) on ATP-induced increases in cytosolic free-calcium concentration ([Ca2+]i) were investigated in the CHP-234 human neuroblastoma cell line. Adenosine Triphosphate 50-53 neuropeptide Y Homo sapiens 42-45 9020878-2 1997 Pretreatment of cells with 100 nM NPY potentiated the increase in [Ca2+]i evoked subsequently by 20 microM ATP, compared with initial application of ATP in a control experiment, whereas a similar pretreatment with 1 microM NPY attenuated the subsequent response to ATP. Adenosine Triphosphate 107-110 neuropeptide Y Homo sapiens 34-37 9020878-2 1997 Pretreatment of cells with 100 nM NPY potentiated the increase in [Ca2+]i evoked subsequently by 20 microM ATP, compared with initial application of ATP in a control experiment, whereas a similar pretreatment with 1 microM NPY attenuated the subsequent response to ATP. Adenosine Triphosphate 149-152 neuropeptide Y Homo sapiens 34-37 9020878-2 1997 Pretreatment of cells with 100 nM NPY potentiated the increase in [Ca2+]i evoked subsequently by 20 microM ATP, compared with initial application of ATP in a control experiment, whereas a similar pretreatment with 1 microM NPY attenuated the subsequent response to ATP. Adenosine Triphosphate 149-152 neuropeptide Y Homo sapiens 34-37 9020878-7 1997 It is concluded that NPY has a biphasic modulatory effect on increases in [Ca2+]i produced by ATP, which probably involves the cAMP/protein kinase A cascade. Adenosine Triphosphate 94-97 neuropeptide Y Homo sapiens 21-24 2773656-0 1989 Does clonidine- or neuropeptide Y-mediated inhibition of ATP secretion from sympathetic nerves operate primarily by increasing a potassium conductance? Adenosine Triphosphate 57-60 neuropeptide Y Homo sapiens 19-33 8016410-0 1994 Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Adenosine Triphosphate 114-117 neuropeptide Y Homo sapiens 0-14 2455195-4 1987 Examples include the interactions of neuropeptide Y (NPY) with noradrenaline (NA) and adenosine 5"-triphosphate (ATP) released from some sympathetic nerves; vasoactive intestinal polypeptide (VIP) with acetylcholine (ACh) released from some parasympathetic nerves; and NPY and 5-hydroxytryptamine (5-HT) released from intracardiac neurones supplying coronary vessels. Adenosine Triphosphate 113-116 neuropeptide Y Homo sapiens 37-51 2455195-4 1987 Examples include the interactions of neuropeptide Y (NPY) with noradrenaline (NA) and adenosine 5"-triphosphate (ATP) released from some sympathetic nerves; vasoactive intestinal polypeptide (VIP) with acetylcholine (ACh) released from some parasympathetic nerves; and NPY and 5-hydroxytryptamine (5-HT) released from intracardiac neurones supplying coronary vessels. Adenosine Triphosphate 113-116 neuropeptide Y Homo sapiens 53-56